Human Trials of Gene Therapy Born in Spain Against Alzhéimer Begin: Improves Memory and Neuroinflammation
13 Articles
13 Articles
Opens a new pathway for patients with moderate dementia, a group with few therapeutic options
The treatment has been developed in a laboratory of the Cajal Institute of the Higher Council of Scientific Research (CSIC).
El Periódico
In animal models it has achieved promising results acting on several pathways associated with pathology
Álvaro Pascual-Leone announces the first human trial of TET101, a gene therapy designed to act on basic mechanisms to curb the disease of oblivion Read
noticiasdealava.eus
Tetraneuron biotechnology has reported that its gene therapy TET-101 to treat moderate Alzheimer's, developed in a laboratory of the Cajal Institute of the Higher Council of Scientific Research (CSIC), has received authorization in Australia to initiate the first assessment of its safety and therapeutic potential in humans.
Tetraneuron biotechnology has reported that its gene therapy TET-101 to treat moderate Alzheimer's, developed in a laboratory of the Cajal Institute of the Higher Council of Scientific Research (CSIC), has received authorization in Australia to initiate the first assessment of its safety and therapeutic potential in humans.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
